

Drug Discovery Toxicology Specialty Section

ANNUAL REPORT: 2023–2024
May 1, 2023 to April 30, 2024

I. Officers:

<u>2023–2024</u>	<u>2024–2025</u>
President: Jonathan Maher Vice President: Satoko Kiyota Vice President-Elect: Wenyue Hu Secretary-Treasurer: Marianna Stamou Past President, Councilor: Brandon Jeffy Councilor: Laura Armstrong Councilor: Lauren Lewis Postdoctoral Representative: Dakota Robarts Graduate Student Representative: Zakiyah Henry	President: Satoko Kiyota Vice President: Wenyue Hu Vice President-Elect: Marianna Stamou Secretary-Treasurer: Sarah Carratt Past President, Councilor: Jonathan Maher Councilor: Laura Armstrong Councilor: Brita Kilburg-Basnyat Postdoctoral Representative: Dakota Robarts Graduate Student Representative: Zakiyah Henry

II. 2024 Membership total: 271

III. Key Outcomes and Accomplishments in 2023–2024:

The Drug Discovery Toxicology Specialty Section accomplished the following activities throughout the year.

- In-person meeting/mixer
- Mentoring/career development events
- Trainee awards conferred
- Paper of the year award
- Newsletter(s)
- Webinars
- Business meeting (communicated operations/finances to members)

IV. Collaborative Partnerships with Other SOT Organizations:

The Drug Discovery Toxicology Specialty Section collaborated with the following organizations within SOT.

- Computational Toxicology

V. Communication Methods:

The Drug Discovery Toxicology Specialty Section stayed in contact with its members throughout the year through the following mechanisms.

- ToXchange
- Emails through SOT Headquarters
- Specialty Section website
- Newsletter(s)

- Through Graduate Student/Postdoc Representatives
- LinkedIn

VI. Promotion of Inclusivity

The Drug Discovery Toxicology Specialty Section maintained an inclusive organization through the following activities.

- Nominate a diverse slate of candidates for elections
- Solicit equitable input from all executive committee leaders
- Utilize virtual meetings for convening Specialty Section leadership
- Utilize standardized rubrics for judging awards/posters
- Highlight trainee research
- Use multiple approaches to communicate with membership

VII. Mentoring and Career Development Activities:

The Drug Discovery Toxicology Specialty Section hosted the following mentoring activities throughout the year for its membership.

- Mentoring luncheon for students and postdocs at the annual meeting

VIII. Awards Given:

Trainee	6
Early Career	6
Mid Career	0
Late Career	0

IX. Key Outcomes and Improvements:

DDTSS was the primary endorser for a CE course and symposium session and an additional endorser for four sessions at the 2024 SOT Annual Meeting. DDTSS hosted a reception at the 2024 SOT Annual Meeting in Salt Lake City. There was a brief business meeting which included a report of section activities in the past year, award announcements, introductions of the 2023-2024 officers, and ample networking opportunities to connect with colleagues.

X. Strategic Plan:

The Drug Discovery Toxicology Specialty Section supported the following SOT Strategic Priorities.

- Proactively pursue impactful scientific content
- Support the development and application of tools that advance toxicology
- Effectively communicate scientific advances
- Foster connectivity across scientific disciplines
- Develop a talent pool of toxicologists for the future
- Provide training and education that reflects the needs of members
- Provide mentoring and networking opportunities for all career levels
- Enhance member recognition and visibility at all levels

XI. Scientific Topics of Interest:

The Drug Discovery Toxicology Specialty Section is interested in seeing the following topic areas developed into sessions at future SOT Annual Meetings.

- Safety assessments of novel technology in drug development; How we can compile available information (safety, biology, competitor's info, etc) into a meaningful visualization to increase efficiency for toxicologist to understand safety concerns and form

XII. Feedback to the Society:

A. What is the one thing the Society should be doing that it currently does not do (or does not do effectively) that would be of importance/benefit to the members of the Specialty Section?

No feedback at this time.

B. What is the one thing the Society is currently doing that impacts the Specialty Section that should be changed (e.g., stopped, modified, etc.)?

No feedback at this time.